Association of COVID-19 and Cancer: Risk Statistics and Management of COVID-19 in Cancer Patients

Shahzar Khan, Hasnain Jan, Shah Faisal, Ayyaz Khan, Rashida Ilyas, Khadija Bibi, Sadeeq ur Rehman

Abstract


COVID-19 is extremely lethal disease and almost 190 countries is suffering from the latest pandemic. The literature indicates that COVID-19 is more prevalent in patients with compromised immune systems. Patients with cancer are particularly vulnerable to COVID-19 because of immune compromised condition due to immunosuppressive therapy. Immunotherapy results in mixing or overlap of COVID-19 associated pneumonia and immune-related pneumonitis and thus makes the diagnosis process very confusing. On the other side in this pandemic, treating cancer patients in hospital will bring a lot of risk. There is still no strong evidence on the cancer-COVID-19 connection. Yet, in this pandemic, patients with cancer should be treated as special cases. Risk management is highly needed in the critical time of this pandemic. This review highlights the association between COVID-19 and cancer, also the strategy to minimize the risk of COVID-19 in cancer patients.


Keywords


COVID-19, Cancer, Immunosuppressive therapy, Risk

Full Text:

PDF

References


Huang C et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395(10223):497-506. doi.org/10.1016/S0140-6736(20)30183-5

Zhu N et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 2020. doi: 10.1056/NEJMoa2001017

Jan H et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries, 2020. 8(2). doi: 10. 15190/d.2020.5

Baloch S et al. The Coronavirus Disease 2019 (COVID-19) Pandemic. The Tohoku Journal of Experimental Medicine, 2020. 250(4):271-278. doi. org/10. 1620/tjem.250.271

Bai, Y et al. Presumed asymptomatic carrier transmission of COVID-19. Jama, 2020. 323(14):1406-1407. doi:10.1001/jama.2020.2565

Tyrrell D and M Bynoe. Cultivation of viruses from a high proportion of patients with colds. Lancet, 1966.

Lillie PJ et al. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. Journal of Infection, 2020. 80(5):578-606. doi.org/10.1016/j.jinf.2020.02.020

Liang W et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology, 2020. 21(3):335-337. doi.org/10.1016/S1470-2045(20)30096-6

Yu J et al. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. medRxiv, 2020. doi.org/10.1101/2020.02.22.20025320

Xia Y et al. Risk of COVID-19 for patients with cancer. The Lancet Oncology, 2020. 21(4):180. doi.org/10.1016/S1470-2045(20)30150-9

Picchianti DA et al. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. International Journal of Molecular Sciences, 2020. 21(9):3330. doi.org/10.3390/ijms21093330

Smith JC and Sheltzer JM. Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2. bioRxiv, 2020. doi.org/10.1101/2020.03.28.013672

Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Future Medicine. 2020. doi.org/10.2217/imt-2020-0067

Mehta P et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 2020. 395(10229):1033-1034. doi.org/10.1016/S0140-6736(20)30628-0

Postow MA, Sidlow R, and Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 2018. 378(2):158-168. doi: 10.1056/NEJMra1703481

Russell CD, Millar JE, and Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet, 2020. 395(10223):473-475. doi: 10.1016/j.jtho.2020.02.025

Zhang H, Huang Y, and Xie C. The treatment and outcome of a lung cancer patient infected with SARS-CoV-2. Journal of Thoracic Oncology, 2020. doi: 10.1016/j.jtho.2020.02.025

Hwang DM et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern pathology, 2005. 18(1):1-10. doi.org/10.1038/modpathol.3800247

Franks TJ et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Human pathology, 2003. 34(8):743-748. doi.org/10.1016/S0046-8177(03)00367-8

Tian S et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of Thoracic Oncology, 2020. doi.org/10.1016/j.jtho.2020.02.010

Bonomi L et al. A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab. Journal of Thoracic Oncology, 2020. doi.org/10.1016/j.jtho.2020.03.021

Wu Z and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama, 2020. 323(13):1239-1242. doi:10.1001/jama.2020.2648

Cai H. Sex difference and smoking predisposition in patients with COVID-19. The Lancet Respiratory Medicine, 2020. 8(4):e20. doi.org/10. 1016/S2213-2600(20)30117

Chen N et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020. 395(10223):507-513. doi.org/10.1016/S0140-6736(20)30211-7

Beaver K et al. Comparing hospital and telephone follow‐up for patients treated for stage–I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG: An International Journal of Obstetrics & Gynaecology, 2017. 124(1):150-160. doi.org/10.1111/1471-0528.14039

Frankland J et al. Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme. BMC cancer, 2019. 19(1):368. doi.org/10.1186/s12885-019-5561-0

Schmidt-Hansen M, Baldwin DR and Hasler E. What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of Thoracic Oncology, 2012. 7(5):821-824. doi.org/10.1097/JTO.0b013e31824afc55

Cusack M and Taylor C. A literature review of the potential of telephone follow‐up in colorectal cancer. Journal of Clinical Nursing, 2010. 19(17‐18):2394-2405. doi.org/10.1111/j.1365-2702.2010.03253.

Pignon JP et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and oncology, 2009. 92(1):4-14. doi.org/10.1016/j.radonc.2009.04.014

Remuzzi A and Remuzzi G. COVID-19 and Italy: what next? The Lancet, 2020. doi.org/10.1016/S0140-6736(20)30627-9

Goel AN et al. The impact of treatment package time on survival in surgically managed head and neck cancer in the United States. Oral oncology, 2019. 88:39-48. doi.org/10.1016/j.oraloncology.2018.11.021

Song S et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer, 2013. 119(2):325-331. doi.org/10.1002/cncr.27652

Mao L et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology, 2020. doi:10.1001/jamaneurol.2020.1127

Roder D et al. Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival. BMJ open, 2019. 9(9):e031421. doi: 10.1136/bmjopen-2019-031421

Kucejko RJ et al. How Soon Should Patients With Colon Cancer Undergo Definitive Resection? Diseases of the Colon & Rectum, 2020. 63(2): 172-182. doi: 10.1097/DCR.0000000000001525

Delisle M et al. The Association Between Wait Times for Colorectal Cancer Treatment and Health Care Costs: A Population-Based Analysis. Diseases of the Colon & Rectum, 2020. 63(2):160-171. doi: 10.1097/DCR.0000000000001517

Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians, 2019. 69(1):7-34. doi.org/10.3322/caac.21551

Mehta P et al. Correspondence COVID-19: consider cytokine storm syndromes and. Lancet, 2020. 6736(20):19-20. doi. org/10. 1016/S0140-6736(20)30628.

Shewan, L.G., A.J.S. Coats, and M. Henein. Authors’ Responsibilities and Ethical Publishing. in International Cardiovascular Forum Journal. 2018. DOI: 10.17987/icfj. v13i0. 525




DOI: https://doi.org/10.17987/icfj.v20i0.691

Copyright (c) 2020 The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.